• LifeMD Reports Third Quarter 2023 Results; Record Revenue and Adjusted EBITDA

    Source: Nasdaq GlobeNewswire / 08 Nov 2023 16:05:02   America/New_York

    • Revenue increased 23% year-over-year to $38.6 million with both telehealth and WorkSimpli achieving record revenues.
    • Adjusted EPS of $0.08 per share compared with a loss of $0.03 in the year-ago period.
    • Consolidated adjusted EBITDA increased to $2.8 million compared with a loss of $0.8 million in the year-ago period, and a 60% improvement versus the second quarter of 2023.
    • Weight Management revenue more than quadrupled versus the second quarter of 2023.
    • Telehealth subscribers grew 22% year-over-year to a record 207,000 patients.

    Conference call begins at 4:30 p.m. Eastern time today

    NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today reported financial results for the three and nine months ended September 30, 2023.

    Management Commentary

    “During the third quarter of 2023 LifeMD achieved record revenue and adjusted EBITDA, largely driven by significant patient subscriber growth. Our GLP-1 Weight Management program alone added over 8,000 net new patients, ending the quarter with over 10,000, a number that has grown to over 16,000 today. Central to this acceleration is our industry-leading telehealth technology platform, complemented by an incredible provider network spanning all 50 states,” said Justin Schreiber, Chairman and CEO of LifeMD. “Our lifestyle healthcare businesses, led by RexMD, once again posted double-digit revenue growth with robust bottom-line margins that continued to exceed 30%. We also made sizeable progress in leveraging our best-in-class platform to drive meaningful B2B partnerships, including the execution of an agreement with Ascend Therapeutics to service the women’s health market and a joint marketing and sales agreement with IQVIA leveraging LifeMD’s tremendous telehealth infrastructure with IQVIA’s comprehensive commercialization solutions. We expect to execute additional opportunities in the near future. Given our sustained record performance and LifeMD’s leadership in key telehealth markets, including weight management with GLP-1s, I believe we are extremely well positioned for continued growth next year.”

    “We finished the third quarter with outstanding top- and bottom-line financial results, with revenue increasing 23% and adjusted EBITDA increasing to a record $2.8 million. For the second consecutive quarter we achieved positive cash flow from operations and exited the third quarter with our strongest balance sheet and liquidity position ever. All of these factors continue to position 2023 to be a tremendous year for LifeMD while setting the stage for what we believe will be breakout performance in 2024,” commented Marc Benathen, Chief Financial Officer of LifeMD.

    Third Quarter Financial Highlights

    • Revenue increased 23% year-over-year to $38.6 million.
    • Telehealth revenue increased 14% versus the year-ago period and 9% sequentially. WorkSimpli revenue increased 42% versus the year-ago period.
    • Telehealth active subscribers increased 22% over the year-ago period to approximately 207,000.
    • Weight Management revenue more than quadrupled sequentially.
    • WorkSimpli active subscribers increased 14% over the year-ago period to approximately 170,000.
    • LifeMD branded Virtual Primary Care products and services subscribers finished the third quarter at over 26,000 with over 10,000 active patients on our GLP-1 Weight Management platform.
    • Gross margin expanded to a record 88%, up from 85% in the year-ago period.
    • GAAP net loss was $6.9 million or $0.20 per share, compared with GAAP net loss of $8.1 million or $0.26 per share in the year-ago period.
    • Adjusted EBITDA increased to $2.8 million compared with a loss of $0.8 million in the year-ago period (see definition below of this non-GAAP financial measure and reconciliation to GAAP).
    • Adjusted diluted EPS was $0.08 compared with a loss of $0.03 in the year-ago period (see definition below of this non-GAAP financial measure and reconciliation to GAAP).
    • Second consecutive quarter of positive cash flow from operations and exited the quarter with $15.3 million of cash.

    Third Quarter Key Performance Metrics 

    ($ in 000s) Three Months Ended Sept 30, Y-o-Y
    Key Performance Metrics 20232022 % Growth
    Revenue     
    Telehealth $24,343 $21,365  14%
    WorkSimpli $14,271 $10,047  42%
    Total Revenue $38,614 $31,412  23%
          
    Subscription Revenue as % of Total  96% 95% 1%
          
    Active Subscribers     
    Telehealth Active Subscribers  206,536  169,916  22%
    WorkSimpli Active Subscribers  170,388  149,095  14%
    Total Active Subscribers  376,924  319,011  18%
               

    Financial Guidance

    For the fourth quarter of 2023, the Company expects:

    • Revenue to be between $40 million and $41 million.
    • Adjusted EBITDA to be between $3 million and $4 million.

    For the full year 2023, the Company expects:

    • Revenue to be between $148 million and $149 million.
    • Adjusted EBITDA to be between $10 and $11 million.

    Guidance for 2023 includes a $4.0 million impact of deferred revenue related to GAAP accounting rules for the Weight Management business. Net of this impact, both revenue and adjusted EBITDA would be higher by $4.0 million.

    Conference Call

    LifeMD’s management will host a conference call today at 4:30 p.m. Eastern time to discuss the Company’s financial results and outlook, and answer questions. Details for the call are as follows:

    Toll-free dial-in number: 877-704-4453
    International dial-in number: 201-389-0920
    Conference ID: 13741419
       

    A replay of the webcast will be available in the Investors section of the Company’s website at ir.lifemd.com.

    About LifeMD

    LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s health, women’s health, allergy & asthma, and dermatology. Leveraging a vertically-integrated, proprietary digital care platform, a 50-state affiliated medical group, and a US-based patient care center, LifeMD is elevating healthcare by increasing access to top-notch and affordable care. For more information, please visit LifeMD.com.

    Cautionary Note Regarding Forward Looking Statements

    This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.

    Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.

    Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.

    Investor Contact
    LifeMD, Inc.
    Marc Benathen, CFO
    marc@lifemd.com

    Media Contact
    press@lifemd.com

    Tables to Follow

     
    LIFEMD, INC.
    CONDENSED CONSOLIDATED BALANCE SHEETS
     
     September 30, 2023 December 31, 2022
     (Unaudited)   
    ASSETS
          
    Current Assets     
    Cash$15,288,330  $3,958,957 
    Accounts receivable, net 4,418,582   2,834,750 
    Product deposit 84,768   127,265 
    Inventory, net 3,790,646   3,703,363 
    Other current assets 1,303,960   687,022 
    Total Current Assets 24,886,286   11,311,357 
          
    Non-current Assets     
    Equipment, net 424,637   476,441 
    Right of use asset 799,104   1,206,009 
    Capitalized software, net 11,325,766   8,840,187 
    Intangible assets, net 3,255,231   3,831,859 
    Total Non-current Assets 15,804,738   14,354,496 
          
    Total Assets$40,691,024  $25,665,853 
          
    LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' DEFICIT     
          
    Current Liabilities     
    Accounts payable$9,637,390  $10,106,793 
    Accrued expenses 15,493,128   12,166,509 
    Notes payable, net 426,223   2,797,250 
    Current operating lease liabilities 725,832   756,093 
    Deferred revenue 6,239,354   5,547,506 
    Total Current Liabilities 32,521,927   31,374,151 
          
    Long-term Liabilities     
    Long-term debt, net 18,827,283   - 
    Noncurrent operating lease liabilities 169,821   574,136 
    Contingent consideration 256,250   443,750 
    Purchase price payable -   579,319 
    Total Liabilities 51,775,281   32,971,356 
          
    Commitments and Contingencies     
    Mezzanine Equity     
    Preferred Stock, $0.0001 par value; 5,000,000 shares authorized     
    Series B Preferred Stock, $0.0001 par value; 5,000 shares authorized, zero and 3,500 shares issued and outstanding, as of September 30, 2023 and December 31, 2022, respectively. Liquidation value approximately $0 and $1,305 per share as of September 30, 2023 and December 31, 2022, respectively -   4,565,822 
          
    Stockholders’ Deficit     
    Series A Preferred Stock, $0.0001 par value; 1,610,000 shares authorized, 1,400,000 shares issued and outstanding, liquidation value approximately $29.44 and $27.84 per share as of September 30, 2023 and December 31, 2022, respectively 140   140 
    Common Stock, $0.01 par value; 100,000,000 shares authorized, 34,759,250 and 31,552,775 shares issued, 34,656,210 and 31,449,735 outstanding as of September 30, 2023 and December 31, 2022, respectively 347,593   315,528 
    Additional paid-in capital 196,901,377   179,015,250 
    Accumulated deficit (209,756,573)  (190,562,994)
    Treasury stock, 103,040 and 103,040 shares, at cost, as of September 30, 2023 and December 31, 2022, respectively (163,701)  (163,701)
    Total LifeMD, Inc. Stockholders’ Deficit (12,671,164)  (11,395,777)
    Non-controlling interest 1,586,907   (475,548)
    Total Stockholders’ Deficit (11,084,257)  (11,871,325)
    Total Liabilities, Mezzanine Equity and Stockholders’ Deficit$40,691,024  $25,665,853 
          

     

    LIFEMD, INC.
    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
    (Unaudited)
                 
      Three Months Ended September 30, Nine Months Ended September 30,
      2023 2022 2023 2022
    Revenues            
    Telehealth revenue, net $24,342,789  $21,365,178  $66,896,719  $66,231,202 
    WorkSimpli revenue, net  14,271,122   10,047,291   40,790,439   24,682,602 
    Total revenues, net  38,613,911   31,412,469   107,687,158   90,913,804 
    Cost of revenues            
    Cost of telehealth revenue  4,479,760   4,502,919   12,525,887   14,042,112 
    Cost of WorkSimpli revenue  301,746   213,923   1,019,018   558,216 
    Total cost of revenues  4,781,506   4,716,842   13,544,905   14,600,328 
                 
    Gross profit  33,832,405   26,695,627   94,142,253   76,313,476 
                 
    Expenses             
    Selling and marketing expenses  19,776,797   17,200,859   56,062,345   60,928,649 
    General and administrative expenses  13,398,387   12,385,030   36,120,723   37,757,710 
    Other operating expenses  1,622,137   1,617,375   4,640,690   5,076,820 
    Customer service expenses  2,106,252   1,488,428   5,573,734   3,428,098 
    Development costs  1,498,213   821,636   4,062,498   1,951,039 
    Goodwill impairment charge  -   -   -   2,735,000 
    Change in fair value of contingent consideration  -   248,000   -   (2,487,000)
    Total expenses  38,401,786   33,761,328   106,459,990   109,390,316 
                 
    Operating loss  (4,569,381)  (7,065,701)  (12,317,737)  (33,076,840)
                 
    Other expenses            
    Interest expense, net  (713,766)  (132,235)  (1,973,901)  (432,405)
    (Loss) gain on debt extinguishment  -   -   (325,198)  63,400 
                 
    Net loss  (5,283,147)  (7,197,936)  (14,616,836)  (33,445,845)
                 
    Net income attributable to noncontrolling interests  839,288   83,737   2,247,055   154,464 
                 
    Net loss attributable to LifeMD, Inc.  (6,122,435)  (7,281,673)  (16,863,891)  (33,600,309)
                 
    Preferred stock dividends  (776,563)  (776,563)  (2,329,688)  (2,329,688)
                 
    Net loss attributable to LifeMD, Inc. common stockholders $(6,898,998) $(8,058,236) $(19,193,579) $(35,929,997)
                 
    Basic loss per share attributable to LifeMD, Inc. common stockholders $(0.20) $(0.26) $(0.58) $(1.17)
    Diluted loss per share attributable to LifeMD, Inc. common stockholders $(0.20) $(0.26) $(0.58) $(1.17)
                 
    Weighted average number of common shares outstanding:            
    Basic  34,472,904   30,935,643   32,959,665   30,830,533 
    Diluted  34,472,904   30,935,643   32,959,665   30,830,533 
                 

     

    LIFEMD, INC.
     CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 
     (Unaudited) 
                 
      Three Months Ended September 30, Nine Months Ended September 30,
      2023 2022 2023 2022
             
    CASH FLOWS FROM OPERATING ACTIVITIES            
    Net loss $(5,283,147) $(7,197,936) $(14,616,836) $(33,445,845)
    Adjustments to reconcile net loss to net cash provided by (used in) operating activities:            
    Amortization of debt discount  79,653   -   233,495   - 
    Amortization of capitalized software  1,439,049   770,873   3,787,716   1,746,899 
    Amortization of intangibles  245,968   325,495   725,496   666,782 
    Accretion of consideration payable  34,265   37,373   148,481   172,741 
    Depreciation of fixed assets  49,852   43,761   146,286   117,008 
    Loss (gain) on debt extinguishment  -   -   325,198   (63,400)
    Change in fair value of contingent consideration  -   248,000   -   (2,487,000)
    Goodwill impairment charge  -   -   -   2,735,000 
    Operating lease payments  191,645   172,836   562,073   463,198 
    Stock issued for legal settlement  532,000   816,000   532,000   816,000 
    Stock compensation expense  3,318,253   3,336,213   8,843,736   11,850,000 
                 
    Changes in Assets and Liabilities            
    Accounts receivable  (750,039)  (24,491)  (1,583,832)  (1,558,063)
    Product deposit  150,347   332,790   42,497   95,505 
    Inventory  (92,344)  (710,889)  (87,283)  (2,052,363)
    Other current assets  (631,765)  58,629   (616,938)  (21,386)
    Change in operating lease liability  (201,667)  (167,644)  (589,744)  (378,095)
    Deferred revenue  571,144   360,650   691,848   853,272 
    Accounts payable  44,011   (1,026,708)  (469,403)  1,827,103 
    Accrued expenses  1,378,992   (150,954)  5,611,131   (2,303,466)
    Other operating activity  -   -   (579,319)  - 
    Net cash provided by (used in) operating activities  1,076,217   (2,776,002)  3,106,602   (20,966,110)
                 
    CASH FLOWS FROM INVESTING ACTIVITIES            
    Cash paid for capitalized software costs  (2,373,443)  (2,220,018)  (6,273,295)  (6,742,946)
    Purchase of equipment  (30,263)  (21,546)  (94,482)  (378,877)
    Purchase of intangible assets  -   -   (148,868)  (4,000,500)
    Acquisition of business, net of cash acquired  -   -   -   (1,012,395)
    Net cash used in investing activities  (2,403,706)  (2,241,564)  (6,516,645)  (12,134,718)
                 
    CASH FLOWS FROM FINANCING ACTIVITIES            
    Proceeds from long-term debt, net  4,993,885   -   19,466,887   - 
    Proceeds from notes payable  347,691   -   2,347,691   - 
    Sale of common stock under ATM, net  899,567   -   899,567   - 
    Repayment of notes payable, net of prepayment penalty  (657,002)  -   (5,043,916)  - 
    Cash proceeds from exercise of options  -   -   -   90,400 
    Cash proceeds from exercise of warrants  -   -   -   38,500 
    Preferred stock dividends  (776,563)  (776,563)  (2,329,688)  (2,329,688)
    Contingent consideration payment for ResumeBuild  (62,500)  (62,500)  (187,500)  (93,750)
    Net payments for membership interest of WorkSimpli  -   12,150   (305,625)  12,150 
    Distributions to non-controlling interest  (36,000)  (36,000)  (108,000)  (108,000)
    Net cash provided by (used in) financing activities  4,709,078   (862,913)  14,739,416   (2,390,388)
                 
    Net increase (decrease) in cash  3,381,589   (5,880,479)  11,329,373   (35,491,216)
                 
    Cash at beginning of period  11,906,741   11,717,302   3,958,957   41,328,039 
                 
    Cash at end of period $15,288,330  $5,836,823  $15,288,330  $5,836,823 
                 
    Cash paid for interest            
    Cash paid during the period for interest $717,054  $-  $1,485,242  $- 
                 
    Non-cash investing and financing activities:            
    Warrants issued for debt instruments $(215,243) $-  $873,100  $- 
    Cashless exercise of options $579  $42  $744  $297 
    Consideration payable for Cleared acquisition $-  $-  $-  $8,079,367 
    Consideration payable for ResumeBuild acquisition $-  $-  $-  $500,000 
    Stock issued for noncontingent consideration payment $642,000  $-  $1,926,000  $- 
    Series B Preferred Stock conversion $5,072,814  $-  $5,072,814  $- 
    Principal of Paycheck Protection Program loans forgiven $-  $-  $-  $63,400 
    Right of use asset $62,053  $-  $155,168  $- 
    Right of use lease liability $62,053  $-  $155,168  $- 
                     

    About the Use of Non-GAAP Financial Measures:
    To supplement our financial information presented in accordance with GAAP, we use adjusted EBITDA and adjusted EPS as non-GAAP financial measures to clarify and enhance an understanding of past performance. We believe that the presentation of these financial measures enhances an investor’s understanding of our financial performance. We further believe that these financial measures are useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors.

    Adjusted EBITDA is defined as income (loss) attributable to common shareholders before interest, taxes, depreciation, amortization, accretion, financing transaction expense, non-controlling interests, foreign currency translation, inventory valuation, sales return reserves, litigation costs, loss on debt extinguishment, dividends, insurance acceptance and Sarbanes-Oxley readiness, acquisition costs, severance expenses and stock-based compensation expense. We have provided below a reconciliation of adjusted EBITDA to net loss attributable to common shareholders, its most directly comparable GAAP financial measure.

    Adjusted EPS is defined as the diluted net loss attributable to LifeMD, Inc common shareholders before interest, taxes, depreciation, amortization, accretion, financing transaction expense, non-controlling interests, foreign currency translation, inventory valuation, sales return reserves, litigation costs, loss on debt extinguishment, dividends, insurance acceptance and Sarbanes-Oxley readiness, acquisition costs, severance expenses and stock-based compensation expense. We have provided below a reconciliation of adjusted EPS to Diluted loss per share attributable to LifeMD, Inc common shareholders, its most directly comparable GAAP financial measure.

    We believe the above financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the terms adjusted EBITDA and adjusted EPS may vary from that of others in our industry. Adjusted EBITDA and adjusted EPS should not be considered as an alternative to net loss before taxes, net loss per share, operating loss or any other performance measures derived in accordance with GAAP as measures of performance. 

             
    Reconciliation of GAAP Net Loss to Adjusted EBITDA
    (in whole numbers, unaudited)
     Three Months Ended September 30, Nine Months Ended September 30,
     2023 2022 2023 2022
    Net loss attributable to common shareholders $(6,898,998) $(8,058,236) $(19,193,579) $(35,929,997)
            
    Interest expense (excluding amortization of debt discount)  594,229   17,550   1,233,415   92,090 
    Depreciation, amortization and accretion expense  1,769,134   1,177,502   4,807,979   2,703,430 
    Amortization of debt discount  79,653   -   233,495   - 
    (Gain) loss on debt extinguishment  -   -   325,198   (63,400)
    Financing transactions expense  305,424   -   735,501   152,015 
    Litigation costs  420,404   813,000   1,426,330   1,517,359 
    Inventory and reserve adjustment  -   -   232,630   230,661 
    Severance costs  7,692   -   7,692   179,090 
    Acquisitions expenses  86,942   -   127,138   265,153 
    Change in fair value of contingent consideration  -   248,000   -   (2,487,000)
    Goodwill impairment charge  -   -   -   2,735,000 
    Insurance acceptance readiness  8,094   -   66,634   - 
    Sarbanes Oxley readiness  48,576   -   48,576   - 
    Accrued interest on Series B Convertible Preferred Stock  39,884   114,685   506,991   340,315 
    Foreign exchange (gain) loss  272,899   685,242   796,619   685,242 
    Taxes  70,378   -   70,378   - 
    Dividends  1,813,130   776,563   3,971,890   2,329,688 
    Stock-based compensation expense  3,318,253   3,336,213   8,843,736   11,850,000 
    Net income attributable to noncontrolling interests  839,288   83,737   2,247,055   154,464 
            
    Adjusted EBITDA $2,774,982  $(805,744) $6,487,678  $(15,245,890)

     

            
    Reconciliation of GAAP Diluted Loss per Share Attributable to
    Common Shareholders to Adjusted EPS
    (unaudited)Three Months Ended
    September 30,
     Nine Months Ended
    September 30,
     2023 2022 2023 2022
    Diluted loss per share attributable to LifeMD, Inc. common shareholders$(0.20) $(0.26) $(0.58) $(1.17)
            
    Adjustments to Reconcile GAAP Diluted Loss Per Share to Adjusted EPS       
    Interest expense (excluding amortization of debt discount) 0.02   -   0.04   - 
    Depreciation, amortization and accretion expense 0.05   0.04   0.15   0.09 
    Amortization of debt discount -   -   0.01   - 
    Loss on debt extinguishment -   -   0.01   - 
    Financing transactions expense 0.01   -   0.02   - 
    Litigation costs 0.01   0.03   0.04   0.05 
    Inventory and reserve adjustment -   -   0.01   0.01 
    Severance costs -   -   -   0.01 
    Acquisitions expenses -   -   -   0.01 
    Change in fair value of contingent consideration -   0.01   -   (0.08)
    Goodwill impairment charge -   -   -   0.09 
    Insurance acceptance readiness -   -   -   - 
    Sarbanes Oxley readiness -   -   -   - 
    Accrued interest on Series B Convertible Preferred Stock -   -   0.02   0.01 
    Foreign exchange (gain) loss 0.01   0.02   0.02   0.02 
    Taxes -   -   -   - 
    Dividends 0.05   0.02   0.12   0.08 
    Stock-based compensation expense 0.10   0.11   0.27   0.38 
    Net income attributable to noncontrolling interests 0.03   -   0.07   0.01 
     
    Adjusted EPS$0.08  $(0.03) $0.20  $(0.49)

     


    Primary Logo

Share on,